All In Biotech

Drug Trial Radar · NCT01155479

A Placebo- and Active-Controlled Study of Preladenant in Early Parkinson's Disease (PD) (P05664)

A Phase 3, Double-Blind, Double-Dummy, Placebo- and Active-Controlled Dose-Range-Finding Efficacy and Safety Study of Preladenant in Subjects With Early Parkinson's Disease

Last checked: Nov 20, 2026Latest source record: Nov 7, 2018 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registryPivotal-lookingPhase 3. Randomized with 1,022 participants. This is a heuristic, not a regulatory label.

Status

Terminated

Enrollment

1,022

Actual

Start

Jul 6, 2010

Primary completion

Jul 16, 2013

Study completion Jul 16, 2013

Sponsor

Lead sponsor
Merck Sharp & Dohme LLCMerck & Co. (MRK)
Sponsor type
Industry
First posted
Jul 1, 2010

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 30 years, up to 85 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a one year, 2-part study to determine the efficacy and safety of preladenant, an adenosine type 2a (A2a) receptor antagonist. The purpose of Part 1 (first 26 weeks) is to determine if preladenant is effective in the treatment of early Parkinson's Disease. The purpose of Part 2 (second 26 weeks) is to determine if preladenant is safe and well tolerated. The primary efficacy hypothesis is that at least the 10 mg twice daily dose of preladenant is superior to placebo as measured by the change from Baseline to Week 26 in the sum of Unified Parkinson's Disease Rating Scale (UPDRS) Parts 2 and 3 scores (UPDRS2+3).

Conditions

  • Parkinson Disease

Interventions

  • Preladenant 2 mg tabletDrug

    Preladenant 2 mg oral tablet taken twice daily

  • Preladenant 5 mg tabletDrug

    Preladenant 5 mg oral tablet taken twice daily

  • Preladenant 10 mg tabletDrug

    Preladenant 10 mg oral tablet taken twice daily

  • Rasagiline 1 mg capsuleDrug

    Rasagiline 1 mg oral capsule taken once daily

  • Placebo for Rasagiline 1 mg capsuleDrug

    Placebo for rasagiline 1 mg oral capsule taken once daily

  • Placebo for PreladenantDrug

    Placebo for preladenant 2 mg, 5 mg, or 10 mg oral tablet taken twice daily

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline in the Sum of Unified Parkinson's Disease Rating Scale Parts 2 and 3 Scores (UPDRS2+3)Time frame: Baseline and Week 26
  2. Number of Participants With Adverse Events (AEs) in Part 1Time frame: Day 1 to Week 26
  3. Number of Participants Who Discontinued Study Due to an AE in Part 1Time frame: Day 1 to Week 26
  4. Number of Participants With Adverse Events (AEs) in Part 2Time frame: Week 27 to Week 52
  5. Number of Participants Who Discontinued Study Due to an AE in Part 2Time frame: Week 27 to Week 52

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.